• editor@ijmra.in
  • ISSN[Online] : 2643-9875  ||  ISSN[Print] : 2643-9840

VOLUME 03 ISSUE 09 SEPTEMBER 2020

N-acetyl cysteine (NAC) and COVID-19 treatment: New hopes in old medication
1Naser Hatami, 2Navid Kalani, 1*Farshid Javdani, 3Sayyed Reza Ahmadi,
3Seyed Reza Habibzadeh, 4Behzad Shahi,5Fatemeh Maleki, 6Neema John Mehramiz,
3Mahdi Foroughian
1Student Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran.
2Research center for social Determinants of Health, Jahrom University of Medical Sciences, Jahrom, Iran.
3Department of Emergency Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
4Department of Emergency Medicine, Faculty of Medicine, Zahedan University of Medical Sciences, Mashhad, Iran.
5Department of Emergency Medicine, Faculty of Medicine, Birjand University of Medical Sciences, Mashhad, Iran.
6Department of Psychiatry Neurology. Banner university medical center, Tucson, AZ, USA.
Corresponding Author : Farshid Javdani.
Student Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran.
DOI : https://doi.org/10.47191/ijmra/v3-i9-09

Google Scholar Download Pdf
ABSTRACT

N-acetyl cysteine is seen to improve patients with acute respiratory diseases. The recommended pathways, of it's the effect on pulmonary diseases, are its antioxidant capacity through glutathione synthesis (GSH) and following effects on preventing and controlling cytokine storm. These features make it a good candidate to be evaluated for COVID-19 disease as this disease is causing a cytokine storm.

KEYWORDS

N-acetyl cysteine, COVID-19, Acute respiratory distress syndrome

REFERENCES

1) Cao M, Zhang D, Wang Y, Lu Y, Zhu X, Li Y, Xue H, Lin Y, Zhang M, Sun Y, Yang Z. Clinical features of patients infected with the 2019 novel coronavirus (COVID-19) in Shanghai, China. MedRxiv. 2020 Jan 1.

2) Teijaro JR. Cytokine storms in infectious diseases. InSeminars in immunopathology 2017 Jul 1 (Vol. 39, No. 5, pp. 501-503). Springer Berlin Heidelberg.

3) Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet. 2020; 395(10224): e35-e6.

4) Medici TC, Radielovic P. Effects of drugs on mucus glycoproteins and water in bronchial secretion. Journal of International Medical Research. 1979 Sep;7(5):434-42.

5) Dekhuijzen PN. Antioxidant properties of N‐acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. European Respiratory Journal. 2004 Apr 1;23(4):629-36.

6) Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW, Cinatl Jr J. N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochemical pharmacology. 2010 Feb 1;79(3):413-20.

7) Teskey G, Abrahem R, Cao R, Gyurjian K, Islamoglu H, Lucero M, Martinez A, Paredes E, Salaiz O, Robinson B, Venketaraman V. Glutathione as a marker for human disease. InAdvances in clinical chemistry 2018 Jan 1 (Vol. 87, pp. 141-159). Elsevier.

8) Horowitz RI, Freeman PR, Bruzzese J. Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases. Respiratory Medicine Case Reports. 2020 Apr 21:101063.

9) Zhang Y, Ding S, Li C, Wang Y, Chen Z, Wang Z. Effects of N-acetylcysteine treatment in acute respiratory distress syndrome: a meta-analysis. Experimental and therapeutic medicine. 2017 Oct 1;14(4):2863-8

VOLUME 03 ISSUE 09 SEPTEMBER 2020

Our Services and Policies

Authors should prepare their manuscripts according to the instructions given in the authors' guidelines. Manuscripts which do not conform to the format and style of the Journal may be returned to the authors for revision or rejected.

The Journal reserves the right to make any further formal changes and language corrections necessary in a manuscript accepted for publication so that it conforms to the formatting requirements of the Journal.

International Journal of Multidisciplinary Research and Analysis will publish 12 monthly online issues per year,IJMRA publishes articles as soon as the final copy-edited version is approved. IJMRA publishes articles and review papers of all subjects area.

Open access is a mechanism by which research outputs are distributed online, Hybrid open access journals, contain a mixture of open access articles and closed access articles.

International Journal of Multidisciplinary Research and Analysis initiate a call for research paper for Volume 03 Issue 09(September 2020).

PUBLICATION DATES:
1) Last Date of Submission : 25 SEPTEMBER 2020.
2) Article published within a week.
3) Submit Article : editor@ijmra.in or Online

Why with us

International Journal of Multidisciplinary Research and Analysis is better then other journals because:-
1 : IJMRA only accepts original and high quality research and technical papers.
2 : Paper will publish immediately in current issue after registration.
3 : Authors can download their full papers at any time with digital certificate.

The Editors reserve the right to reject papers without sending them out for review.

Authors should prepare their manuscripts according to the instructions given in the authors' guidelines. Manuscripts which do not conform to the format and style of the Journal may be returned to the authors for revision or rejected. The Journal reserves the right to make any further formal changes and language corrections necessary in a manuscript accepted for publication so that it conforms to the formatting requirements of the Journal.

Indexed In
Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar Avatar